Erica Kratz - 01 Sep 2026 Form 4 Insider Report for Aura Biosciences, Inc. (AURA)

Reporting relationship: Chief Reg. & Quality Officer
Issuer ticker: AURA
Reported as of: 01 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Sep 2026, 17:26:38 UTC
Prior SEC filing: 12 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Amy Elazzouzi, as Attorney-in-Fact

Key filing fact

Erica Kratz filed Form 4 for Aura Biosciences, Inc. (AURA) on 01 Sep 2026.

Key facts

This page summarizes Erica Kratz's Form 4 filing for Aura Biosciences, Inc. (AURA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 01 Sep 2026, 17:26.

Change

Previous filing in this sequence was filed on 12 Aug 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002148785 Primary reporting owner

Kratz Erica

Relationship: Chief Reg. & Quality Officer
Address: C/O AURA BIOSCIENCES, INC., 80 GUEST STREET, BOSTON
Signature: /s/ Amy Elazzouzi, as Attorney-in-Fact
Signature date: 01 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AURA transaction

Common Stock

Award

Transaction value
Shares: +100,885
Change %
Price: $0.000000^*
Shares after: 100,885
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AURA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +199,115
Change %
Price: $0.000000^*
Shares after: 199,115
Date: 01 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 199,115
Exercise price: $7.43
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These securities represent an inducement award granted pursuant to a restricted stock unit ("RSU") award agreement with the Issuer. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments, subject to the Reporting Person's continued service as of the relevant vesting date, with the first tranche scheduled to vest on September 15, 2027.

Footnote F2

The option shall vest as follows: 25% of the options vest on August 10, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.